MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waxman, D. J.
Right arrow Articles by Gelboin, H. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waxman, D. J.
Right arrow Articles by Gelboin, H. V.

Monoclonal antibodies inhibitory to rat hepatic cytochromes P-450: P- 450 form specificities and use as probes for cytochrome P-450-dependent steroid hydroxylations

DJ Waxman, DP Lapenson, SS Park, C Attisano and HV Gelboin

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115.

Cytochrome P-450 (P-450) form specificities were established for a total of nine monoclonal antibodies (MAbs) raised to four distinct rat hepatic P-450 enzymes (P-450s 2c, PB-2a, PB-4, and BNF-B), using a combination of enzyme-linked immunosorbent analysis, dot immunoblotting, Western blotting, Ouchterlony immunodiffusion, and immunoinhibition analyses. Four of the MAbs were fully (greater than or equal to 85%) inhibitory toward the corresponding immunoreactive P-450s when assayed in purified, reconstituted enzyme systems, while two of the MAbs were partially inhibitory, with a maximum of 50 or 80% inhibition achieved in the presence of saturating MAb. Inhibitory MAbs reactive with P-450s 2c, 3, and PB-4, respectively, were used to demonstrate that the formation of multiple hydroxytestosterone metabolites by each of the respective purified P-450 enzymes is reflective of their inherent catalytic specificities and not due to the presence of immunochemical distinguishable P-450 enzyme contaminants. P- 450 form-specific contributions to rat hepatic microsomal steroid hormone hydroxylase activities were then assessed using the inhibitory MAbs as probes. MAb-reactive P-450 2c was shown to be the major (greater than or equal to 85%) catalyst of microsomal testosterone and androstenedione 16 alpha-hydroxylation in both untreated and beta- naphthoflavone-induced rats. However, this P-450 form catalyzed only approximately 30% of hepatic microsomal steroid 16 alpha-hydroxylase activity in phenobarbital-induced adult males, and less than or equal to 10% of steroid 16 alpha-hydroxylase activity in (phenobarbital- induced immature males or adult females, where the balance of 16 alpha- hydroxylase activity is catalyzed by MAb-reactive P-450 PB-4. Although MAb-reactive P-450 PB-4 catalyzed the majority (greater than or equal to 90%) of microsomal androstenedione 16 beta-hydroxylation in phenobarbital-induced rats, this P-450 enzyme did not contribute to the low level 16 beta-hydroxylase activity of uninduced liver samples. Finally, MAb-reactive P-450 3 catalyzed at least 85% of microsomal androstenedione 7 alpha-hydroxylation, independent of the age, sex, or induction status of the animals used as source of liver microsomes. These findings demonstrate the usefulness of MAbs as probes for the contributions of individual P-450 enzymes to the metabolism of steroid hormones susceptible to hydroxylation at multiple sites.

Volume 32, Issue 5, pp. 615-624, 11/01/1987
Copyright © 1987 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
R. Stadel, J. Yang, J. W. Nalwalk, J. G. Phillips, and L. B. Hough
High-Affinity Binding of [3H]Cimetidine to a Heme-Containing Protein in Rat Brain
Drug Metab. Dispos., March 1, 2008; 36(3): 614 - 621.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A.-L. Minn, H. Pelczar, C. Denizot, M. Martinet, J.-M. Heydel, B. Walther, A. Minn, H. Goudonnet, and Y. Artur
CHARACTERIZATION OF MICROSOMAL CYTOCHROME P450-DEPENDENT MONOOXYGENASES IN THE RAT OLFACTORY MUCOSA
Drug Metab. Dispos., August 1, 2005; 33(8): 1229 - 1237.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
C. A. Wiwi, M. Gupte, and D. J. Waxman
Sexually Dimorphic P450 Gene Expression in Liver-Specific Hepatocyte Nuclear Factor 4{alpha}-Deficient Mice
Mol. Endocrinol., August 1, 2004; 18(8): 1975 - 1987.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
B. S. Cummings, R. C. Zangar, R. F. Novak, and L. H. Lash
Cellular Distribution of Cytochromes P-450 in the Rat Kidney
Drug Metab. Dispos., April 1, 1999; 27(4): 542 - 548.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
S.-H. Park, X. Liu, L. Hennighausen, H. W. Davey, and D. J. Waxman
Distinctive Roles of STAT5a and STAT5b in Sexual Dimorphism of Hepatic P450 Gene Expression. IMPACT OF Stat5a GENE DISRUPTION
J. Biol. Chem., March 12, 1999; 274(11): 7421 - 7430.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. K. H. Chang, M. D. Anderson, S. M. Bandiera, and G. D. Bellward
Effect of Ovariectomy and Androgen on Phenobarbital Induction of Hepatic CYP2B1 and CYP2B2 in Sprague-Dawley Rats
Drug Metab. Dispos., August 1, 1997; 25(8): 994 - 1000.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. B. Udy, R. P. Towers, R. G. Snell, R. J. Wilkins, S.-H. Park, P. A. Ram, D. J. Waxman, and H. W. Davey
Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression
PNAS, July 8, 1997; 94(14): 7239 - 7244.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1987 by the American Society for Pharmacology and Experimental Therapeutics